Linsitinib
- Generic Name
- Linsitinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23N5O
- CAS Number
- 867160-71-2
- Unique Ingredient Identifier
- 15A52GPT8T
- Background
An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Sling Therapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT06112340
- Locations
- 🇺🇸
Bascom Palmer Eye Institute, Miami, Florida, United States
🇺🇸West Virginia University Eye Institute, Morgantown, West Virginia, United States
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
- Conditions
- Interventions
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Sling Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05276063
- Locations
- 🇺🇸
Bascom Palmer Eye Institute, Miami, Florida, United States
🇺🇸Sarasota Retina Institute, Sarasota, Florida, United States
🇺🇸Mass Eye and Ear, Boston, Massachusetts, United States
Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 16
- Registration Number
- NCT02546544
- Locations
- 🇳🇱
Department of Clinical Oncology, Leiden University Medical Center, Leiden, Postzone K1-P, Netherlands
🇮🇹Istituti Ortopedici Rizzoli, Bologna, Italy
🇫🇷Universitè Lyon 1 Claude Bernard, Lyon, France
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
- Conditions
- Interventions
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02057380
- Locations
- 🇺🇸
Site US10004, La Jolla, California, United States
🇺🇸Site US10006, Tampa, Florida, United States
🇺🇸Site US10002, Baltimore, Maryland, United States
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT01560260
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-02-15
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT01533181
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
- First Posted Date
- 2012-02-15
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT01533246
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)
- Conditions
- Interventions
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT01465815
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.